Inflammation

Resource Center

News
Research Summaries
Resources
FDA Alerts From the Journal
Insights
Podcasts Q&As Videos
Interactive
Polls Quizzes Slideshows

Research Summaries

risk management
risk management
COVID-19 Roundup: Variant Component in Boosters, Damage to Cardiac Muscle, Hypertension Risk
08/15/2022
In this COVID-19 roundup, coverage includes the addition of an Omicron variant component to future vaccine boosters, the relationship between a COVID-19 infection and damage to heart muscle, and how...
08/15/2022
Inflammation
Inflammation
FDA Approves First and Only Subcutaneous Option for CIDP
03/16/2018
The US Food and Drug Administration approved the drug after trials showed a lower rate of relapse in chronic inflammatory demyelinating polyneuropathy or withdrawal for any other reason.
03/16/2018
FDA ALERT
fda
FDA ALERT
FDA Approves Interchangeable Biosimilar for Psoriatic Arthritis, Other Inflammatory Conditions
11/08/2015

Anthony Calabro, MA

Anthony Calabro, MA
The FDA approved ustekinumab-auub as an interchangeable biosimilar with ustekinumab for multiple inflammatory diseases.
11/08/2015
Research Summary
research summary
Research Summary
Can Maintaining Immunosuppressants Reduce Relapse Rates for Patients with Stable Immunoglobulin G4-Related Disease?
10/02/2015
Miranda Manier, BA
: A multicenter, randomized controlled trial revealed that continuing immunosuppressants, with or without low-dose glucocorticoids, significantly reduces relapse rates for patients with stable IgG4-related...
10/02/2015